Trial · NCT03086369
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine | 3 | |
| Overall Study | STARTED | Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 7 | |
| Overall Study | STARTED | Phase1b (Cohort Expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 12 | |
| Overall Study | STARTED | Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine | 82 | |
| Overall Study | STARTED | Phase 2: Placebo + Nab-paclitaxel + Gemcitabine | 80 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine | 3 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 7 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase1b (Cohort Expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 12 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine | 81 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Placebo + Nab-paclitaxel + Gemcitabine | 78 | |
| Overall Study | COMPLETED | Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine | 2 | |
| Overall Study | COMPLETED | Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 7 | |
| Overall Study | COMPLETED | Phase1b (Cohort Expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 12 | |
| Overall Study | COMPLETED | Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine | 73 | |
| Overall Study | COMPLETED | Phase 2: Placebo + Nab-paclitaxel + Gemcitabine | 73 | |
| Overall Study | NOT COMPLETED | Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine | 1 | |
| Overall Study | NOT COMPLETED | Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 0 | |
| Overall Study | NOT COMPLETED | Phase1b (Cohort Expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine | 0 | |
| Overall Study | NOT COMPLETED | Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine | 9 | |
| Overall Study | NOT COMPLETED | Phase 2: Placebo + Nab-paclitaxel + Gemcitabine | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03086369/flow